Premium
P1–058: The Hsp90 co‐chaperone FKBP51 produces neurotoxic tau oligomers: Implication for aging and Alzheimer's disease
Author(s) -
Blair Laura,
Nordhues Bryce,
Hill Shan,
Scaglione K. Matthew,
O'Leary John,
Breydo Leonid,
Bo Zhang,
Li Pengfei,
Wang Lily,
Cotman Carl,
Paulson Henry,
Muschol Martin,
Uversky Vladimir,
Klengel Torsten,
Binder Elisabeth,
Kayed Rakez,
Berchtold Nicole,
Golde Todd,
Dickey Chad
Publication year - 2013
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.05.279
Subject(s) - neurodegeneration , hsp90 , heat shock protein , tau protein , fkbp5 , chaperone (clinical) , microbiology and biotechnology , chemistry , biology , alzheimer's disease , biochemistry , medicine , pathology , gene , disease , glucocorticoid receptor
genotype. Statistical analysis was performed on carriers of the rs45455403 genotype, to determine its predictor value for specific cognitive features. Over 80 neurological characteristics were explored for significant differences between the wild-type and the rs45455403 polymorphism carriers. Results: Observed cognitive differences between the wild-type and the rs45455403 polymorphism carriers included processing speed, naming, word-finding difficulties, problems with verbal repetition, reading, judgment, following instructions, sense of direction, anxiety, and insight to memory loss. Thesewere observed even in subjects without overt symptoms of dementia. An additional 100 specimens from African-American individuals with careful cognitive profiling are currently undergoing genetic analysis. Conclusions: Studying the cognitive spectrum of patients carrying the rs45455403 genotype can help identify the earliest manifestations of Alzheimer’s disease in this African-American sub-group. Clinical characterization of this genetic subgroup may assist the identification of at-risk individuals or the clinical biomarkers for early diagnosis and/or progression. Current research suggests that early disease-modifying interventions or prevention strategies are highly effective for at-risk patients.